Manchester spin-out Imperagen raises £5M seed to build faster enzyme engineering with AI and quantum physics — TFN

Imperagen, based in Manchester, closed a £5 million seed round led by PXN Ventures

The company combines quantum simulation, custom AI models, and robotic lab automation into a closed-loop system that improves with every experiment

Imperagen improved enzyme performance by more than 500 times in just five development cycles

Imperagen, a UK-based deeptech, raised £5 million in seed funding led by PXN Ventures, with ongoing support from IQ Capital and Northern Gritstone.

The Manchester spin-out, founded in 2021 by Dr Andrew Almond, Dr Andrew Currin, and Dr Tim Eyes, is building a closet that uses quantum custom AI models and lab automation to design enzymes faster and more predictably than traditional methods.